Dr.
Reddy’s Laboratories (Dr. Reddy’s), Established in 1984, and is headquartered
in Hyderabad, India. It is India’s second-largest pharmaceutical company
20,000+ Employees 40 Nationalities Commercial presence in 25 Countries Revenue
2,400 Millons (Approx. 2.4 Billons).
- First Indian-company launched Para IV product, Fluoxetine, in USA World’s first generic monoclonal antibody of Rituximab Reditux Several complex generics launched in USA with fewer than three competitors, e.g., Fondaparinux
- Ranked first among biotech and pharmaceutical companies in India by Great Place to Work in its Best Companies to Work For survey, in 2013.
- Reddy’s started marketing biosimilar products Such as rituximab, pegfi lgrastim, darbepoetin
Main
Segments for Revenue:
- Pharmaceutical Services & Active Ingredients
- Global Generics Access to affordable medicines
- Proprietary Products fulfilling unmet medical needs in dermatology & neurology
DR Reddy’s Milestones
- 1994 Dr Reddy's Labs starts targeting US generic market 2000 Sets up a lab in Atlanta, Reddy US Therapeutics Inc
- 2001 Dr Reddy's Labs completes US initial public offering of $132.8 mn American depository receipts issue; listed on NYSE
- 2002 Dr Reddy's Labs starts European operations by acquiring two pharmaceutical firms in the UK 2006 Dr Reddy’s Labs crosses $500 mn in revenues
- 2005-2010 Globalizing and growing inorganically
- Acquires OctoPlus N.V., Netherlands, a service-based specialty pharma company to strengthens capabilities in proprietary drug delivery technologies and difficult-to-formulate APIs
- 2014 - Accelerates global access to affordable and innovative medicines